Follow us on Twitter
twitter icon@FreshPatents


Quinoline patents

      

This page is updated frequently with new Quinoline-related patent applications.




 Organic electroluminescent materials and devices patent thumbnailOrganic electroluminescent materials and devices
Novel phosphorescent metal complexes containing 2-phenylisoquinoline ligands with at least two substituents on the isoquinoline ring are provided. The disclosed compounds have low sublimation temperatures that allow for ease of purification and fabrication into a variety of oled devices..
Universal Display Corporation


 Inhibitors of jmjd2c as anticancer agents patent thumbnailInhibitors of jmjd2c as anticancer agents
The present disclosure provides compounds, pharmaceutical compositions and related methods for the treatment of cancer, e.g., castration-resistant prostate cancer (crpc). Specifically, the present disclosure provides a series of 8-hydroxyquinoline derivatives which show cytotoxic effects on androgen-independent prostate cancer cells..
The J. David Gladstone Institutes


 Isoquinolinesulfonyl derivative as rho kinase inhibitor patent thumbnailIsoquinolinesulfonyl derivative as rho kinase inhibitor
The present invention discloses a class of isoquinolinesulfonyl derivatives as rho kinase inhibitors, and pharmaceutical compositions thereof, and relates to pharmaceutically acceptable uses thereof. Specifically, the present invention relates to a compound as represented by formula (i), or a pharmaceutically acceptable salt thereof..
Medshine Discovery Inc.


 Novel substituted imidazoquinolines patent thumbnailNovel substituted imidazoquinolines
Imidazoquinolines of formula i that contain substituted amine or amide functionality at 1-position and that are effective as toll like receptor 7 activators are disclosed. These compounds are useful as anticancer agents..
4sc Ag


 Toll-like receptor-7 and -8 modulatory 1h imidazoquinoline derived compounds patent thumbnailToll-like receptor-7 and -8 modulatory 1h imidazoquinoline derived compounds
The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides tlr7 agonists and tlr7/tlr8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof.
The University Of Kansas


 Selective androgen receptor degrader (sard) ligands and methods of use thereof patent thumbnailSelective androgen receptor degrader (sard) ligands and methods of use thereof
This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (sard) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other ar-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, kennedy's disease, amyotrophic lateral sclerosis (als), abdominal aortic aneurysm (aaa), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (ar-fl) including pathogenic and/or resistance mutations, ar-splice variants (ar-sv), and pathogenic polyglutamine (polyq) polymorphisms of ar in a subject.. .
University Of Tennessee Research Foundation


 Combination patent thumbnailCombination
The present invention relates to a method of treating breast cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a breast cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and (s)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1h-pyrano[3′,4′:6,7] indolizino [1,2-b]quinoline-3,14-(4h,12h)-dione, or a pharmaceutically acceptable salt thereof, to a human in need thereof..
Sunnybrook Research Institute


 Use of substitute oxo tetrahydroquinoline sulfonamides or salts thereof for raising stress tolerance of plants patent thumbnailUse of substitute oxo tetrahydroquinoline sulfonamides or salts thereof for raising stress tolerance of plants
Where the radicals in the general formula (i) correspond to the definitions given in the description, for enhancing stress tolerance in plants to abiotic stress, and/or for increasing plant yield.. .

 Polymorphic forms of 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid and its disodium salt, process for their preparation and their use patent thumbnailPolymorphic forms of 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid and its disodium salt, process for their preparation and their use
The present disclosure relates to polymorphic form of pqq and/or its salts represented by formula (i), wherein “n” and “m” are selected from a group consisting of: (a) “n”=3, “m”=0 and (b) “n”=1, “m”=2; and; r3 is na+. The present disclosure also relates to a process for preparing the polymorphic form of compound of formula (i) and/or its salts, a composition comprising the polymorphic form of compound of formula (i) and/or its salts and use thereof..
Anthem Biosciences Private Limited


 Drug therapy for preventing or treating glaucoma patent thumbnailDrug therapy for preventing or treating glaucoma
There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (s)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma..
Kowa Co., Ltd.


Preventive/therapeutic method and preventive/therapeutic agent for complications after cataract surgery

The present invention relates to a preventive/therapeutic method comprising administering to a subject a medicine containing 4-fluoro-5-{[(2s)-2-methyl-1,4-diazepan-1-yl]sulfonyl}isoquinoline (ripasudil) or a salt thereof, or a solvate thereof as an active ingredient.. .

Dietary supplement for improving brain health

Compositions that can be used to improve human health, and in particular brain health are provided. In some embodiments the composition comprises inositol, n-acetyl l-tyrosine, pyrroloquinoline quinone (pqq), choline bitartrate, l-theanine and acetyl-l-carnitine.
Braingear Enterprises, Inc.

Organic electroluminescent materials and devices

This invention discloses novel ligands for metal complexes. These ligands contain a phenyl with an iso-quinoline (or other type of heterocycles) which are bridged together with a carbon substituted by two aliphatic side chains.
Universal Display Corporation

Organic-electroluminescent-element material and organic electroluminescent element using same

Disclosed is an organic electroluminescent device (organic el device) that is improved in luminous efficiency, sufficiently secures driving stability, and has a simple construction. The device is an organic electroluminescent device having organic layers including a light-emitting layer between an anode and a cathode laminated on a substrate, in which a carborane compound is incorporated into at least one layer of the organic layers, or is incorporated as a host material into a light-emitting layer containing a phosphorescent light-emitting dopant and the host material.
Nippon Steel & Sumikin Chemical Co., Ltd.

Quinoline compounds

The present invention relates to quinoline compounds as defined by formula i below. Such quinoline compounds have been shown to inhibit the formation of amyloid deposits (e.g., amyloid oligomers, fibrils or plaques).
Oxford University Innovation Limited

Quinolines as fgfr kinase modulators

The invention relates to new quinoline derivative compounds of formula (i), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. Cancer..
Astex Therapeutics Limited

Benzoquinoline inhibitors of vesicular monoamine transporter 2

The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (vmat2), pharmaceutical compositions thereof, and methods of use thereof.. .
Auspex Pharmaceuticals, Inc.

Blue light polarization film and its manufacturing method, blue backlight and liquid crystal display device

Disclosed are a blue light polarization film and its manufacturing method, as well as a blue backlight and a liquid crystal display device. The blue light polarization film is of a multi-layered film formed by depositing magnesium aluminum hydrotalcite and tri(8-hydroxyquinoline-5-sulfoacid) aluminum alternately.
Beijing Boe Optoelectronics Technology Co., Ltd.

2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition

Various 2-aminoquinoline compounds as can be used, in vivo or in vitro, for selective inhibition of neuronal nitric oxide synthase.. .

Dupa-indenoisoquinoline conjugates

A targeting ligand-cytotoxic drug conjugate, for example, a dupa-indenoisoquinoline conjugate, is useful for treating cancers, e.g., prostate cancer.. .
Purdue Research Foundation

Benzoquinoline inhibitors of vesicular monoamine transporter 2

The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (vmat2), pharmaceutical compositions thereof, and methods of use thereof.. .
Auspex Pharmaceuticals, Inc.

Oncogenic ros1 and alk kinase inhibitor

A compound suitable for treating cancer, in particular nsclc, inhibits activity of oncogenic ros1 kinase and alk kinase. The compound has certain structural components such as a quinoline moiety in the backbone and at least one phenyl-containing moiety in a side chain with a hydrophobic substituent attached to the backbone via an up to 6-membered linking group as well as a further hydrophobic moiety.
Macau University Of Science And Technology

Compositions comprising vitamin c, vitamin e, and coenzyme q10 and use thereof for promoting female fertility and reproductive health

A new composition including substances that prolong and enhance the quality of the female reproductive system; effectively reducing the physiological effects of aging of the female reproductive system. In some aspects, the composition of the present invention includes coenzyme q10, vitamin c, and vitamin e.
Fertilify Inc.

6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and use

And pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein r1, r2, and r3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., nav1.7 and/or nav1.8. Methods for making the compounds are disclosed.

Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases

Processes of preparing pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (compound 1) in form i and a solid dispersion comprising substantially amorphous n-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide (compound 2), methods of treating, lessening the severity of or symptomatically treating cftr mediated diseases, such as cystic fibrosis, methods of administering, and kits thereof are disclosed.. .
Vertex Pharmaceuticals Incorporated

Indenotriphenylene-based iridium complexes for organic electroluminescence device

Wherein a ring represents an imidazole, a pyridine, a quinoline and an isoquinoline, x1-x2 represents a bidentate ligand, and m, n and r1 to r4 are the same definition as described in the present invention.. .

Benzoquinoline inhibitors of vesicular monoamine transporter 2

The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (vmat2), pharmaceutical compositions thereof, and methods of use thereof. (formula (i)).
Auspex Pharmaceuticals, Inc.

Combination therapy

Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog.
Aerie Pharmaceuticals, Inc.

Method of making a benzylisoquinoline alkaloid (bia) metabolite, enzymes therefore

There is provided a method of preparing a benzylisoquinoline alkaloid (bia) metabolite comprising: a. Culturing a host cell under conditions suitable for protein production, including a ph of between about 7 and about 10 said host cell comprising: b.
Valorbec SociÉtÉ En Commandite

Compounds, compositions and associated methods comprising 3-aryl quinolines

Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed..
The United States Government As Represented By The Department Of Veterans Affairs

Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors

The present invention is directed to novel quinoline compounds useful as s-nitrosoglutathione reductase (gsnor) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.. .
Nivalis Therapeutics, Inc.

Therapeutic agent for ocular fundus disease

Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (s)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient..
Kowa Company, Ltd.

Quinoline-based kinase inhibitors

The present disclosure is generally directed to compounds of formula (i) which can inhibit aaki (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting aaki.. .
Bristol-meyers Squibb Company

Arylquinoline, arylquinolone and arylthioquinolone derivatives and use thereof to treat cancer

Arylquinoline derivatives and their use for treating cancer or cancer metastasis is disclosed. The compounds of the subject technology promote cells to secrete a pro-apoptotic tumor suppressor, i.e., prostate apoptosis response-4 (par-4), which in turn promote apoptosis in cancer cells or metastatic cells..
University Of Kentucky Research Foundation

Crystalline forms of a prolyl hydroxylase inhibitor

The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.. .
Fibrogen, Inc.

Selectively substituted quinoline compounds

Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (sle) and lupus nephritis.. .
Eisai R&d Management Co., Ltd.

Compositions and methods of treating a neurodegenerative disease

The present application relates to new uses of 5-ht6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, thereof, and to the combination of 5-ht6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, thereof, with other therapeutic agents for the treatment of a neurodegenerative disease.. .
Axovant Sciences Ltd.

Methods of treating a neurodegenerative disease

The present application relates to new uses of 5-ht6 receptor antagonists, specifically high doses of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, and to the combination of 5-ht6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, with, an acetylcholinesterase inhibitor for the treatment of a neurodegenerative disease.. .
Axovant Sciences, Ltd.

Pharmaceutical compositions for the treatment of cftr mediated diseases

Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (compound 1) in form i and a solid dispersion comprising substantially amorphous n-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide (compound 2), methods of treating, lessening the severity of, or symptomatically treating cftr mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.. .
Vertex Pharmaceuticals Incorporated

Compositions and methods for producing benzylisoquinoline alkaloids

The present invention relates to host cells that produce compounds that are characterized as benzylisoquinolines, as well as select precursors and intermediates thereof. The host cells comprise one, two or more heterologous coding sequences wherein each of the heterologous coding sequences encodes an enzyme involved in the metabolic pathway of a benzylisoquinoline, or its precursors or intermediates from a starting compound.
California Institute Of Technology

Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors

The invention described herein pertains to substituted indenoisoquinoline compounds as described herein, wherein ra, rd, w, x and y are defined herein, pharmaceutical compositions and formulations comprising the indenoisoquinoline compounds, their synthesis, and methods for their use in the treatment and/or prevention of cancer.. .
Purdue Research Foundation

Substituted tetrahydroisoquinoline compounds as factor xia inhibitors

Or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor xia and/or plasma kallikrein which may be used as medicaments..

Substituted piperidinyl-tetrahydroquinolines

The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, raynaud's phenomenon, crest syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.. .
Bayer Pharma Aktiengesellschaft

4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor

Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.. .
Glaxosmithkline Llc

Novel solution processable red-emitting iridium (iii) complex and organic electroluminescence device including the same

The present invention relates to a novel solution processable red-emitting iridium (iii) complex. In the iridium (iii) complex, a quinoline-thiophene derivative is introduced as a main ligand and a picolinic acid derivative substituted with a halogen, a substituent having electron transporting properties or a substituent having hole transporting properties is introduced as an ancillary ligand at the para-position relative to the nitrogen atom of picolinic acid.
Pusan National University Industry-university Cooperation Foundation



Quinoline topics:
  • Isoquinolin
  • Praziquantel
  • Carbon Atoms
  • Crystallin
  • Quinoline Derivatives
  • Pharmaceutically Acceptable Salt
  • Alkyl Group
  • Cycloalkyl
  • Pharmaceutically Acceptable Salts
  • Immunodeficiency
  • Retrovirus
  • Viral Infection
  • Human Immunodeficiency Virus
  • Angiogenesis
  • Sulfonamide


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Quinoline for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Quinoline with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.3886

    file did exist - 2360

    0 - 1 - 51